Heterocycle Compounds for Blood-Brain Barrier Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, such as imatinib, face challenges in penetrating the blood-brain barrier due to active pumping out by the P-glycoprotein system, limiting their effectiveness in inhibiting beta-amyloid formation and accumulation, and are not suitable for central nervous system cancers.
Innovation Solution
Development of novel heterocyclic compounds that penetrate the blood-brain barrier and inhibit beta-amyloid formation and accumulation, while also targeting certain kinases, allowing for their use in treating neurodegenerative diseases like Alzheimer's and cancers of the central nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If imatinib is used to inhibit beta-amyloid formation, then Aβ production is reduced, but the compound is actively pumped out of the brain by P-glycoprotein, preventing high concentrations from accumulating in the brain
Solution Approach 1:
The patent modifies the chemical structure of imatinib by changing parameters such as replacing the pyrimidine ring with a pyridine ring and adjusting substituent groups (e.g., introducing fluoro, chloro, or methyl groups at specific positions). These structural parameter changes alter the compound's interaction with P-glycoprotein and its ability to penetrate the blood-brain barrier, enabling effective brain penetration while maintaining kinase inhibition activity.
2Reliability
If existing tyrosine kinase inhibitors are used to treat Alzheimer's disease, then Aβ accumulation is inhibited, but the compounds fail to penetrate the blood-brain barrier effectively
Solution Approach 1:
The patent introduces specific local modifications to the imatinib molecule, such as adding fluorine atoms at the 6-position of the pyridine ring or introducing chloro/methyl groups at the 2-position of the phenyl ring. These localized structural changes create regions of different electronic and steric properties that favorably interact with the blood-brain barrier transport mechanisms while preserving the overall kinase-inhibiting function.
3Reliability
If imatinib is used for treating central nervous system cancers, then kinase activity is inhibited, but the compound is actively pumped out by P-glycoprotein, preventing effective treatment
Solution Approach 1:
The patent creates composite molecular structures by combining the core imatinib scaffold with various heterocyclic rings (pyridine, pyrimidine) and substituent groups (fluoro, chloro, methyl, ethyl). These composite structures leverage the kinase-inhibiting properties of the parent compound while the added heterocyclic and substituent components modify the compound's pharmacokinetic properties to enable effective penetration into the central nervous system.
Data Source
AI summary
The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula (I):which penetrate the blood brain barrier, inhibit the formation and accumulation of beta-amyloid, and are useful in the treatment of neurodegenerative diseases, particularly Alzheimer's disease. Further, the compounds of the present invention inhibit certain kinases, thereby being useful for the treatment of cancers of the central nervous system.